T1	Participants 207 215	patients
T2	Participants 632 640	Patients
T3	Participants 1062 1120	prolonged treatment with PUFA (2 g/die, n = 15) or placebo
T4	Participants 1187 1191	PUFA
T5	Participants 1427 1434	placebo
T6	Participants 1573 1587	placebo group.
